Literature DB >> 29773690

Prevalence and impact of WHO group 3 pulmonary hypertension in advanced idiopathic nonspecific interstitial pneumonia.

Christopher S King1, A Whitney Brown1, Oksana A Shlobin1, Nargues Weir1, Matthew Libre2, Domingo Franco-Palacios3, Shahzad Ahmad4, Steven D Nathan1.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29773690     DOI： 10.1183/13993003.00545-2018

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  2 in total

Review 1.  Group 3 Pulmonary Hypertension: From Bench to Bedside.

Authors:  Navneet Singh; Peter Dorfmüller; Oksana A Shlobin; Corey E Ventetuolo
Journal:  Circ Res       Date:  2022-04-28       Impact factor: 23.213

Review 2.  Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative-Group 3 pulmonary hypertension.

Authors:  Sylvia M Nikkho; Manuel J Richter; Eric Shen; Steven H Abman; Katerina Antoniou; Jonathan Chung; Peter Fernandes; Paul Hassoun; Howard M Lazarus; Horst Olschewski; Lucilla Piccari; Mitchell Psotka; Rajan Saggar; Oksana A Shlobin; Norman Stockbridge; Patrizio Vitulo; Carmine Dario Vizza; Stephen J Wort; Steven D Nathan
Journal:  Pulm Circ       Date:  2022-07-01       Impact factor: 2.886
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.